The awareness of the tumor-biological implications of non-canonical EZH2 functions in cancer progression resulted in the development of next-generation EZH2 inhibitors, which degrade the EZH2 protein [80], and hence are more likely to also target non-canonical EZH2 activities. Here, EZH2 is linked to neoplasm.